<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04319341</url>
  </required_header>
  <id_info>
    <org_study_id>Local/2020/JCG-01</org_study_id>
    <nct_id>NCT04319341</nct_id>
  </id_info>
  <brief_title>Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia</brief_title>
  <acronym>NOH-ADAMTS</acronym>
  <official_title>Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study based on data concerning the first pregnancy treated and followed up after the&#xD;
      diagnosis of oAPS in the NOH-APS cohort, according to clinical results already published; and&#xD;
      on a thematic library collected and preserved at the time of the positive pregnancy test.&#xD;
&#xD;
      ADAMTS 13 will be explored in the available samples defined above: ADAMTS13 antigen (presence&#xD;
      of the molecule), ADAMTS13 activity (VWF proteolysis activity of the molecule), global&#xD;
      autoantibodies against ADAMTS13 (plasma antibodies recognizing solid phase insolubilized&#xD;
      ADAMTS13), these 3 parameters for the description of ADAMTS13 being measured using&#xD;
      commercially available diagnostic kits, ELISA type, Technozyme® range, Technoclone, Vienna,&#xD;
      Austria.&#xD;
&#xD;
      The clinical endpoint evaluated will be the occurrence (yes/no) of preeclampsia, which is&#xD;
      assessed globally, all subtypes combined. Then evaluated according to subtype: late&#xD;
      preeclampsia from 34 weeks, early preeclampsia before 34 weeks, eclampsia (convulsions),&#xD;
      HELLP syndrome, preeclampsia associated with the birth of a small-for-gestational-age child&#xD;
      (defined at percentile 10 of the tables adjusted for gestational age and sex; severe: defined&#xD;
      at percentile 3), preeclampsia associated with a retro-placental hematoma, ...&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The quantification, in vitro, of the activity of ADAMTS13</measure>
    <time_frame>at inclusion (J0)</time_frame>
    <description>ADAMTS13 function, U/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The quantification, in vitro, of ADAMTS13 antigen</measure>
    <time_frame>at inclusion (J0)</time_frame>
    <description>ADAMTS13 antigen, U/ml.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The quantification, in vitro, of ADAMTS13 autoantibodies</measure>
    <time_frame>at inclusion (J0)</time_frame>
    <description>ADAMTS13 autoantibodies, U/ml.</description>
  </primary_outcome>
  <enrollment type="Actual">513</enrollment>
  <condition>Antiphospholipid Antibody Syndrome in Pregnancy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>To study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS</intervention_name>
    <description>ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an initially pure, non-thrombotic oAPS; included in the NOH-APS cohort;&#xD;
        having been followed in Nîmes for their first pregnancy following the diagnosis of oAPS;&#xD;
        N=513.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of frozen plasma samples from the positive pregnancy test blood sample.&#xD;
&#xD;
          -  Adult patients, included in the NOH-APS cohort, who have successfully initiated a new&#xD;
             pregnancy after diagnosis of oAPS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Absence of frozen plasma sample from the blood sample from the positive pregnancy&#xD;
             test.&#xD;
&#xD;
          -  Patient who objected to the use of their data.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Nîmes - Hôpital Universitaire Carémea</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoantibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

